Shanghai RAAS Blood Products Co Ltd Class A - Asset Resilience Ratio

Latest as of December 2025: 2.03%

Shanghai RAAS Blood Products Co Ltd Class A (002252) has an Asset Resilience Ratio of 2.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai RAAS Blood Products Co Ltd Clas (002252) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥765.31 Million

≈ $111.99 Million USD Cash + Short-term Investments

Total Assets

CN¥37.78 Billion

≈ $5.53 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Shanghai RAAS Blood Products Co Ltd Clas.

Liquid Assets Composition Over Time

This chart breaks down Shanghai RAAS Blood Products Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Shanghai RAAS Blood Products Co Ltd Clas total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥765.31 Million	2.03%
Total Liquid Assets	CN¥765.31 Million	2.03%

Asset Resilience Insights

Limited Liquidity: Shanghai RAAS Blood Products Co Ltd Class A maintains only 2.03% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Shanghai RAAS Blood Products Co Ltd Class A Industry Peers by Asset Resilience Ratio

Compare Shanghai RAAS Blood Products Co Ltd Class A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Abivax SA American Depositary Shares NASDAQ:ABVX	Biotechnology	2.58%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Kailera Therapeutics, Inc. Common Stock NASDAQ:KLRA	Biotechnology	64.92%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	78.22%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%

Annual Asset Resilience Ratio for Shanghai RAAS Blood Products Co Ltd Class A (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai RAAS Blood Products Co Ltd Class A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.02%	CN¥765.31 Million ≈ $111.99 Million	CN¥37.80 Billion ≈ $5.53 Billion	-2.86pp
2024-12-31	4.89%	CN¥1.64 Billion ≈ $240.54 Million	CN¥33.63 Billion ≈ $4.92 Billion	+4.27pp
2023-12-31	0.62%	CN¥197.41 Million ≈ $28.89 Million	CN¥31.93 Billion ≈ $4.67 Billion	-0.16pp
2022-12-31	0.78%	CN¥237.77 Million ≈ $34.79 Million	CN¥30.46 Billion ≈ $4.46 Billion	-0.02pp
2021-12-31	0.81%	CN¥219.38 Million ≈ $32.10 Million	CN¥27.24 Billion ≈ $3.99 Billion	-0.22pp
2020-12-31	1.03%	CN¥262.14 Million ≈ $38.36 Million	CN¥25.49 Billion ≈ $3.73 Billion	-1.46pp
2019-12-31	2.49%	CN¥295.40 Million ≈ $43.23 Million	CN¥11.85 Billion ≈ $1.73 Billion	-0.38pp
2018-12-31	2.87%	CN¥327.05 Million ≈ $47.86 Million	CN¥11.40 Billion ≈ $1.67 Billion	-18.83pp
2017-12-31	21.70%	CN¥3.14 Billion ≈ $458.95 Million	CN¥14.46 Billion ≈ $2.12 Billion	+5.39pp
2016-12-31	16.31%	CN¥2.16 Billion ≈ $315.65 Million	CN¥13.23 Billion ≈ $1.94 Billion	+2.35pp
2015-12-31	13.96%	CN¥1.61 Billion ≈ $236.05 Million	CN¥11.56 Billion ≈ $1.69 Billion	+13.94pp
2014-12-31	0.02%	CN¥2.00 Million ≈ $292.66K	CN¥9.38 Billion ≈ $1.37 Billion	-6.32pp
2013-12-31	6.35%	CN¥99.96 Million ≈ $14.63 Million	CN¥1.58 Billion ≈ $230.49 Million	--

pp = percentage points

About Shanghai RAAS Blood Products Co Ltd Class A

SHE:002252 China Biotechnology

Market Cap

$4.84 Billion

CN¥33.10 Billion CNY

Market Cap Rank

#3642 Global

#504 in China

Share Price

CN¥5.02

Change (1 day)

+1.01%

52-Week Range

CN¥4.31 - CN¥6.93

All Time High

CN¥24.72